



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

August 10, 2020

Thomas J. Schuetz, M.D., Ph.D.  
Chief Executive Officer  
Compass Therapeutics, Inc.  
245 First Street  
3rd Floor  
Cambridge, Massachusetts 02142

**Re: Compass Therapeutics, Inc.**  
**Form 8-K**  
**Filed June 23, 2020**  
**File No. 000-55939**

Dear Dr. Schuetz:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences